Sinopharm Group Co. Ltd.
SHTDY · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $286,043 | $289,781 | $294,727 | $295,619 |
| % Growth | -1.3% | -1.7% | -0.3% | – |
| Cost of Goods Sold | $265,268 | $267,469 | $272,784 | $270,378 |
| Gross Profit | $20,775 | $22,312 | $21,943 | $25,241 |
| % Margin | 7.3% | 7.7% | 7.4% | 8.5% |
| R&D Expenses | $123 | $0 | $0 | $0 |
| G&A Expenses | $3,274 | $4,498 | $3,915 | $4,710 |
| SG&A Expenses | $12,505 | $13,189 | $12,383 | $13,086 |
| Sales & Mktg Exp. | $7,845 | $8,679 | $8,479 | $9,038 |
| Other Operating Expenses | $1,005 | $1,156 | $1,338 | $2,117 |
| Operating Expenses | $13,634 | $14,345 | $13,722 | $15,203 |
| Operating Income | $7,142 | $7,967 | $8,222 | $10,376 |
| % Margin | 2.5% | 2.7% | 2.8% | 3.5% |
| Other Income/Exp. Net | $57 | -$1,562 | -$625 | $270 |
| Pre-Tax Income | $7,198 | $6,404 | $7,596 | $10,646 |
| Tax Expense | $1,870 | $1,880 | $1,697 | $2,530 |
| Net Income | $3,458 | $3,346 | $3,704 | $4,949 |
| % Margin | 1.2% | 1.2% | 1.3% | 1.7% |
| EPS | 5.55 | 5.35 | 5.95 | 7.95 |
| % Growth | 3.7% | -10.1% | -25.2% | – |
| EPS Diluted | 5.55 | 5.35 | 5.95 | 7.95 |
| Weighted Avg Shares Out | 623 | 623 | 624 | 623 |
| Weighted Avg Shares Out Dil | 623 | 623 | 624 | 623 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$778 |
| Interest Expense | $457 | $1,137 | $966 | $0 |
| Depreciation & Amortization | $2,233 | $1,206 | $1,150 | $1,011 |
| EBITDA | $9,934 | $10,648 | $9,527 | $13,496 |
| % Margin | 3.5% | 3.7% | 3.2% | 4.6% |